
## Jinsong Lu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/290128/publications.pdf Version: 2024-02-01



LINSONGLU

#	Article	IF	CITATIONS
1	CXCL16/CXCR6 chemokine signaling mediates breast cancer progression by pERK1/2-dependent mechanisms. Oncotarget, 2015, 6, 14165-14178.	1.8	77
2	HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk. Journal of Clinical Investigation, 2018, 128, 5235-5250.	8.2	65
3	Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy. EBioMedicine, 2021, 71, 103560.	6.1	62
4	DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. Cancer Letters, 2019, 442, 242-251.	7.2	44
5	Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncology, The, 2017, 18, 371-383.	10.7	43
6	CD177 modulates the function and homeostasis of tumor-infiltrating regulatory T cells. Nature Communications, 2021, 12, 5764.	12.8	38
7	Added value of mean and entropy of apparent diffusion coefficient values for evaluating histologic phenotypes of invasive ductal breast cancer with MR imaging. European Radiology, 2019, 29, 1425-1434.	4.5	31
8	Association of LncRNA MEG3 polymorphisms with efficacy of neoadjuvant chemotherapy in breast cancer. BMC Cancer, 2019, 19, 877.	2.6	30
9	Downregulated circulating microRNAs after surgery: potential noninvasive biomarkers for diagnosis and prognosis of early breast cancer. Cell Death Discovery, 2018, 4, 21.	4.7	28
10	Weekly paclitaxel and cisplatin as neoadjuvant chemotherapy with locally advanced breast cancer: a prospective, single arm, phase II study. Oncotarget, 2017, 8, 79305-79314.	1.8	26
11	Expression profile analysis of long noncoding RNA in ER-positive subtype breast cancer using microarray technique and bioinformatics. Cancer Management and Research, 2017, Volume 9, 891-901.	1.9	26
12	TIMELESS regulates sphingolipid metabolism and tumor cell growth through Sp1/ACER2/S1P axis in ER-positive breast cancer. Cell Death and Disease, 2020, 11, 892.	6.3	26
13	Identification and integrated analysis of key differentially expressed circular RNAs in ER-positive subtype breast cancer. Epigenomics, 2019, 11, 297-321.	2.1	25
14	For or against Adjuvant Trastuzumab for pT1a-bN0M0 Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures. PLoS ONE, 2014, 9, e83646.	2.5	24
15	The ubiquitin-specific protease USP8 deubiquitinates and stabilizes Cx43. Journal of Biological Chemistry, 2018, 293, 8275-8284.	3.4	23
16	Clinical significance of quantitative <em>HER2</em> gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting. OncoTargets and Therapy, 2018, Volume 11, 801-808.	2.0	21
17	Upregulation of microRNAâ€ʿ1 inhibits proliferation and metastasis of breast cancer. Molecular Medicine Reports, 2020, 22, 454-464.	2.4	21
18	LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication. Journal of Experimental and Clinical Cancer Research, 2021, 40, 205.	8.6	20

Jinsong Lu

#	Article	IF	CITATIONS
19	Effects of serum from breast cancer surgery patients receiving perioperative dexmedetomidine on breast cancer cell malignancy: A prospective randomized controlled trial. Cancer Medicine, 2019, 8, 7603-7612.	2.8	18
20	Elevated expression of Gab1 promotes breast cancer metastasis by dissociating the PAR complex. Journal of Experimental and Clinical Cancer Research, 2019, 38, 27.	8.6	18
21	Predictive and prognostic value of prognostic nutritional index for locally advanced breast cancer. Gland Surgery, 2019, 8, 618-626.	1.1	17
22	Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy. Frontiers in Oncology, 2020, 10, 631.	2.8	17
23	Predictive and prognostic value of PDL1 protein expression in breast cancer patients in neoadjuvant setting. Cancer Biology and Therapy, 2019, 20, 941-947.	3.4	15
24	Chinese expert consensus on the clinical diagnosis and treatment of advanced breast cancer (2018). Cancer, 2020, 126, 3867-3882.	4.1	15
25	Raman Nanotagsâ€Guided Intraoperative Sentinel Lymph Nodes Precise Location with Minimal Invasion. Advanced Science, 2022, 9, e2102405.	11.2	15
26	National consensus in China on diagnosis and treatment of patients with advanced breast cancer. Annals of Translational Medicine, 2015, 3, 242.	1.7	14
27	Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study. Clinical Cancer Research, 2022, 28, 3677-3685.	7.0	14
28	Predictive and prognostic value of ZEB1 protein expression in breast cancer patients with neoadjuvant chemotherapy. Cancer Cell International, 2019, 19, 78.	4.1	10
29	Linc00665 Can Predict the Response to Cisplatin-Paclitaxel Neoadjuvant Chemotherapy for Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 604319.	2.8	10
30	Single-nucleotide polymorphism in microRNA-binding site of SULF1 target gene as a protective factor against the susceptibility to breast cancer: a case-control study. OncoTargets and Therapy, 2016, 9, 2749.	2.0	7
31	Polymorphisms in microRNA let-7 binding sites of the HIF1AN and CLDN12 genes can predict pathologic complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer. Annals of Translational Medicine, 2019, 7, 138-138.	1.7	7
32	Single nucleotide polymorphisms of let-7-related genes increase susceptibility to breast cancer. American Journal of Translational Research (discontinued), 2019, 11, 1748-1759.	0.0	7
33	Novel lymphocyte to red blood cell ratio (LRR), neutrophil to red blood cell ratio (NRR), monocyte to red blood cell ratio (MRR) as predictive and prognostic biomarkers for locally advanced breast cancer. Gland Surgery, 2019, 8, 627-635.	1.1	6
34	SHP-2-Mediated Upregulation of ZEB1 Is Important for PDGF-B-Induced Cell Proliferation and Metastatic Phenotype in Triple Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 1230.	2.8	6
35	A single-nucleotide polymorphism of the beta 2-adrenergic receptor gene can predict pathological complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer. Breast Cancer: Targets and Therapy, 2018, Volume 10, 201-206.	1.8	5
36	Ultrasound-Guided Breast Biopsy: Improved Accuracy of 10-G Cable-Free Elite Compared With 14-G CCNB. Journal of Surgical Research, 2020, 247, 172-179.	1.6	5

Jinsong Lu

#	Article	IF	CITATIONS
37	HIF1α Regulates IL17 Signaling Pathway Influencing Sensitivity of Taxane-Based Chemotherapy for Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 729965.	3.7	5
38	Advances in treatment of metastatic breast cancer with bone metastasis. Chinese Clinical Oncology, 2018, 7, 31-31.	1.2	5
39	LncRNA MIR205HG expression predicts efficacyÂof neoadjuvant chemotherapy for patients with locally advanced breast cancer. Genes and Diseases, 2022, 9, 837-840.	3.4	5
40	Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer: an updated meta-analysis of published randomized trials. OncoTargets and Therapy, 2017, Volume 10, 3155-3168.	2.0	4
41	Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different <scp>CYP2D6</scp> genotypes: A propensityâ€score matched cohort study. International Journal of Cancer, 2022, 150, 1664-1676.	5.1	4
42	Prognostic effect of menstrual cycle on timing of surgery in premenopausal breast cancer patients. American Journal of Surgery, 2015, 210, 506-511.	1.8	3
43	Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094088.	3.2	3
44	The Predictive Value of Pre-therapeutic Serum Gamma-glutamyl transferase in Efficacy and Adverse Reactions to Neoadjuvant Chemotherapy among Breast Cancer Patients. Journal of Breast Cancer, 2020, 23, 509.	1.9	3
45	Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes. OncoTargets and Therapy, 2015, 8, 2665.	2.0	2
46	The impact of EGFR gene polymorphisms on the response and toxicity derived from neoadjuvant chemotherapy for breast cancer. Gland Surgery, 2020, 9, 925-935.	1.1	2
47	Association of Neo-Family History Score with pathological complete response, safety, and survival outcomes in patients with breast cancer receiving neoadjuvant platinum-based chemotherapy: An exploratory analysis of two prospective trials. EClinicalMedicine, 2021, 38, 101031.	7.1	2
48	Early breast cancer patients benefit more from longer course chemotherapy: a matched-pair analysis. Future Oncology, 2019, 15, 1781-1789.	2.4	1
49	A multicenter, cross-sectional research of the adherence to endocrine therapy with selective estrogen receptor modulators (SERMs) in premenopausal women in China Journal of Clinical Oncology, 2016, 34, e12025-e12025.	1.6	1
50	Programmed death-ligand 1 single nucleotide polymorphism affects breast cancer chemosensitivity and adverse events in the neoadjuvant setting. International Journal of Biological Markers, 2020, 35, 38-49.	1.8	1
51	Predictive value of lncRNA LOC100505851 in breast cancer in the neoadjuvant setting. Gland Surgery, 2021, 10, 1899-1909.	1.1	0
52	Abstract P2-12-02: Efficacy, safety and survival of neoadjuvant chemotherapy with different estrogen deprivation stratified by menstrual status versus chemotherapy alone in locally advanced breast cancer (SHPD002)—— A randomized multicentre, open-label, phase 3 Triab. Cancer Research, 2022, 82, P2-12-02-P2-12-02.	0.9	0